Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
Phase II Treatment Closed 18 and over Pharmaceutical / Industry D4200C00058
NCT00410761

Trial Description

Summary

The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors.

Eligibility Criteria

Inclusion Criteria:

Confirmed diagnosis of unresectable, locally advanced or metastatic hereditary or sporadic Medullary Thyroid Cancer.

Presence of measurable tumor

Able to swallow medication

Exclusion Criteria:

Major surgery within 4 weeks before randomization

Last dose of prior chemotherapy received less than 4 weeks prior to randomization

Radiation therapy within the last 4 weeks prior to randomization(with exception of palliative radiotherapy)

Brain metastases or spinal cord compression, unless treated at least 4 weeks before first dose and stable without steroid treatment for 10 days

Significant cardiac events

Previous ZD6474 treatment

Trial Contact Information

Trial Lead Organizations/Sponsors

AstraZeneca Pharmaceuticals LP

Peter Langmuir, MD

Study Director

Samuel Wells, MD

Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00410761
Information obtained from ClinicalTrials.gov on May 01, 2009

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.